Clinical Trial Update: Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the intra-articular IL-10 fusion protein F8IL10 for rheumatoid arthritis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• F8IL10

Snippet

Sponsor: Philogen S.p.A. | Conditions: Rheumatoid Arthritis | Phase 1 | Status: WITHDRAWN